Remarkably, our present study showed that there were more baseline tissue CD8+PD-1+ T cells in responders compared to non-responders (Figure 5D), suggesting the presence of previously activated and potentially tumor reactive CD8 T cells in responders to BCG immunotherapy. This evidence concerns the gene CD8A and neoplasm.